Table 5.

One-way sensitivity analysis results showing absolute annual cost of control outcomes with once-weekly semaglutide 0.5 and 1.0 mg, and dulaglutide 0.75 and 1.5 mg in 2018 US dollars

Endpoint	Once-weekly semaglutide 0.5 mg (USD)	Once-weekly semaglutide 1.0 mg (USD)	Dulaglutide 0.75 mg (USD)	Dulaglutide 1.5 mg (USD)
HbA1c ≤ 6.5%	17,996	13,161	25,936	18,762
Proportion reaching target + 1 SE; − 1 SE	16,997–19,121	12,649–13,717	24,002–28,209	17,677–19,990
Including daily SMBG tests	18,965	13,870	27,331	19,772
HbA1c < 7.0%	12,968	11,162	16,958	13,161
Proportion reaching target + 1 SE; − 1 SE	12,475–13,502	10,840–11,505	16,065–17,956	12,648–13,718
Including daily SMBG tests	13,666	11,763	17,870	13,870
HbA1c < 7.0% without hypoglycemia, and no weight gain	13,778	11,916	20,041	15,204
Proportion reaching target + 1 SE; − 1 SE	13,207–14,401	11,522–12,339	18,814–21,440	14,491–15,991
Including daily SMBG tests	14,520	12,558	21,120	16,022
Weight loss ≥ 5%	20,041	13,997	38,340	29,394
Proportion reaching target + 1 SE; − 1 SE	18,818–21,435	13,404–14,645	34,671–42,877	27,008–32,242
Including daily SMBG tests	21,120	14,750	40,403	30,975
Weight loss ≥ 10%	62,987	32,660	293,939	110,227
Proportion reaching target + 1 SE; − 1 SE	55,114–73,485	29,828–36,086	221,199–437,960	92,154–137,118
Including daily SMBG tests	66,376	34,417	309,755	116,158
≥ 1.0% HbA1c reduction and ≥ 3.0% weight loss	16,638	12,968	35,273	25,195
Proportion reaching target + 1 SE; − 1 SE	15,781–17,593	12,474–13,503	32,061–39,199	23,354–27,350
Including daily SMBG tests	17,533	13,666	37,171	26,550